Expression of CXCR4 in Patients With Systemic Lupus Erythematosus

Sohag University

Status: Unknown

Conditions: Systemic Lupus Erythematosus

Study type: Observational

Funder types: Other

Identifiers

NCT04799730

Soh-Med-21-03-01

Details and patient eligibility

About

The objective of this study is to estimate the possible role of CD184 in the pathogenesis of SLE; comparing its level among SLE cases to healthy controls.

Full description

Detection of CXCR4 (CD184) expression on CD19+ B cells by flow cytometry in patients of SLE, comparing its level in the development of lupus activity and pathogenic process of SLE internal organ involvement/ mucocutaneus and/or musculoskeletal involvement. Identify this correlation will be useful for clarifying other accessory factors to improve the diagnosis, better treatment strategy, follow up as well as prognosis for these patients

Enrollment: 100 estimated patients

Sex: All

Ages: 16 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Confirmed SLE patients diagnosed and fulfilled the SLE classification criteria according to the 2019 ACR/EULAR classification criteria for SLE (Aringer et al., 2019)
• Willing and agreed to be included in the study.

Exclusion criteria

• Childhood SLE.
• SLE-patients will refuse to consent to this study.
• Other autoimmune diseases.
• Known or suspected malignancies, especially B cell lymphoma.

Trial design

100 participants in 3 patient groups

SLE cases in remission

Description:

according to SLE Disease Activity Index (SLEDAI) inactive disease will be considered as SLEDAI \<5

SLE cases in activity

Description:

according to SLE Disease Activity Index (SLEDAI) Active disease will be defined as SLEDAI ≥ 5

Control group

Description:

Healthy age and sex matched subjects.